The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC).
R. M. Connolly
No relevant relationships to disclose
M. A. Rudek
No relevant relationships to disclose
H. L. Mc Leod
No relevant relationships to disclose
E. Garrett-Mayer
No relevant relationships to disclose
S. C. Jeter
No relevant relationships to disclose
L. A. Wright
No relevant relationships to disclose
V. Stearns
No relevant relationships to disclose
D. K. Armstrong
No relevant relationships to disclose
J. H. Fetting
No relevant relationships to disclose
S. P. Watkins
No relevant relationships to disclose
N. E. Davidson
No relevant relationships to disclose
A. C. Wolff
Research Funding - Genentech; Roche